Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $6.7 million.

  • Immunome's Share-based Compensation rose 3791.91% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.3 million, marking a year-over-year increase of 7678.75%. This contributed to the annual value of $15.7 million for FY2024, which is 15306.12% up from last year.
  • As of Q3 2025, Immunome's Share-based Compensation stood at $6.7 million, which was up 3791.91% from $5.3 million recorded in Q2 2025.
  • Immunome's Share-based Compensation's 5-year high stood at $6.7 million during Q3 2025, with a 5-year trough of $1.0 million in Q2 2023.
  • For the 3-year period, Immunome's Share-based Compensation averaged around $3.6 million, with its median value being $3.2 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 35170.82% in 2024, then soared by 3791.91% in 2025.
  • Over the past 3 years, Immunome's Share-based Compensation (Quarter) stood at $2.9 million in 2023, then surged by 89.73% to $5.5 million in 2024, then rose by 23.35% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $5.3 million for Q2 2025, and $5.7 million during Q1 2025.